Fate Therapeutics (NASDAQ:FATE) and Translate Bio (NASDAQ:TBIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.
This is a summary of current recommendations and price targets for Fate Therapeutics and Translate Bio, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings and Valuation
This table compares Fate Therapeutics and Translate Bio’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Fate Therapeutics||$4.11 million||266.89||-$42.95 million||($1.02)||-16.65|
Translate Bio has lower revenue, but higher earnings than Fate Therapeutics.
Insider and Institutional Ownership
84.9% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 49.5% of Translate Bio shares are owned by institutional investors. 9.9% of Fate Therapeutics shares are owned by insiders. Comparatively, 1.9% of Translate Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Fate Therapeutics and Translate Bio’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Translate Bio beats Fate Therapeutics on 5 of the 9 factors compared between the two stocks.
About Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; ToleraCyte for the treatment of autoimmune and inflammatory diseases; and FT300 iPSC-derived myeloid derived suppressor cell product candidate for the treatment of autoimmune diseases. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf engineered T-cell product candidates; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells; and a collaboration agreement with ONO Pharmaceutical Co., Ltd. for the development and commercialization of two off-the-shelf CAR-T cell product candidates. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
About Translate Bio
Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.